Washington, DC, April 1, 2014 --- In the largest randomized, double-blind, placebo controlled study to date on the effect of OnabotulinumtoxinA (as known as Botox) on depression, researchers found that more than half of subjects suffering from moderate to severe depression showed a substantial improvement (greater than or equal to 50% of baseline) in their depressive symptoms as measured by the MADRS scale.
The study, conducted by Dr. Eric Finzi, MD, PhD and Dr. Norman E. Rosenthal, MD and published in the Journal of Psychiatric Research, included 74 depressed subjects injected with a single treatment of either onabotulinumtoxinA (OBA) or a placebo to the corrugator and procerus muscles between the eyebrows. Results showed that depressive symptoms (as assessed by the MADRS scale) in the OBA treatment group decreased 47 percent after six weeks, compared to 21 percent in the placebo group. This study is the first to show a significant difference in remission rate with OBA in depressed patients (27% OBA vs. 7% placebo).
Study co-author Dr. Norman E. Rosenthal, MD, Clinical Professor of Psychiatry at Georgetown Medical School, commented, "This research is groundbreaking because it offers those who suffer from depression and their doctors an entirely new approach to treating the condition - one that doesn't conflict with any other treatments."
The study showed that Botox may help relieve depressive symptoms both as a stand-alone and an adjunctive treatment.
"This new research supports earlier facial feedback theory of Charles Darwin and William James which suggests that facial expressions influence mood," added Dr. Eric Finzi, Dermasurgeon and co-author on the paper that first reported that inhibition of frowning by facial injection of OBA could help depressed patients in a pilot study published in 2006.
Notes for editors
This article "Treatment of depression with onabotulinumtoxinA: A randomized, double-blind, placebo controlled trial" by Eric Finzi and Norman E. Rosenthal, is published in Journal of Psychiatric Research, Volume 52 (May 2014). DOI: http://dx.doi.org/10.1016/j.jpsychires.2013.11.006 published by Elsevier.
Full text of the article is available to credentialed journalists upon request; contact firstname.lastname@example.org. Journalists wishing to interview the authors may contact Michelle Delino
+1 202 486 7622, email@example.com.
About The Journal of Psychiatric Research
Journal of Psychiatric Research,founded in 1961, is an international journal with editorial offices in Germany and the United States. It is dedicated to reporting innovative and timely studies in psychiatry and cognate disciplines. http://www.journals.elsevier.com/journal-of-psychiatric-research
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+31 20 485 3877
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.